

Interventions for mild to moderate permanent childhood hearing impairments identified by neonatal hearing screening

Submission date 25/04/2003	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 25/04/2003	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 24/07/2012	Condition category Ear, Nose and Throat	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Adrian Davis

Contact details

MRC Institute of Hearing Research
University Park
University of Nottingham
Nottingham
United Kingdom
NG7 2RD
+44 (0)161 275 8821

Additional identifiers

Protocol serial number

HTA 98/39/02

Study information

Scientific Title

Study objectives

1. To determine by a prospective, longitudinal clinical trial the effectiveness and cost effectiveness of habilitation, including amplification, for children with mild to moderate hearing impairment.
2. To assess the appropriateness of earlier rather than later amplification in this group of children by randomly varying the age at which amplification is introduced into the habilitation. Major outcomes include acceptance, benefit and use of amplification, development of speech, language and communication, quality of life and quality of family life including social, emotional and behavioural aspects.
3. To determine the most cost-effective target criteria for the UK national universal neonatal hearing screening programme.

Strand 1: Qualitative workshops to determine

- i. An agreed set of principles for the development of protocols for the clinical trial
- ii. Current practice and beliefs of professionals and parents to refine the range of clinical equipoise necessary for an RCT in this area
- iii. The best recruitment strategies for districts and families
- iv. The best ways to provide family support using health and education services
- v. Ways of minimising family anxiety about early screening and intervention
- vi. Optimum early initial amplification fitting strategies and fine tuning procedures.

Strand 2: A clinical trial of intervention for mild to moderately hearing impaired children identified by neonatal screening with randomised allocation to groups 1-3 based on the age at which hearing aids are fitted (1=6 months, 2=11-13 months, 3=17-19 months) compared with comparison groups 4-6 (4=mild to moderate hearing impaired detected at 24-36 months, 5=moderate hearing impaired children detected and aided early, 6=normal hearing). The trial will be carried out at children's hearing services in UK districts using targeted or universal neonatal hearing screening.

Details of this study can also be found at: <http://www.hta.ac.uk/project/1238.asp>

Please note that, as of 17 January 2008, the start and end date of this trial have been updated from 1 April 2000 and 1 April 2005 to 1 April 2001 and 31 October 2007, respectively.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration.

Primary study design

Observational

Study design

Longitudinal clinical trial

Study type(s)

Screening

Health condition(s) or problem(s) studied

Ear, nose and throat diseases

Interventions

An intervention package for children with mild to moderate hearing impairment will be assessed for appropriateness, effectiveness and cost effectiveness. The package has two components:

- i. Quality family support, including personal support and an information package on hearing loss and language development (in written and video form)
- ii. Appropriate amplification at an age that is randomly assigned in the region of clinical equipoise.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

The societal costs (direct and indirect) associated with the different interventions will be estimated together with the associated benefits in terms of quality of life (including quality of family life and detailed behavioural and emotional aspects of development). The major outcomes assessed on 4 occasions (ages 9-12, 15-18, 21-24 months and final visit) will be (i) compliance with amplification, (ii) expressive and receptive speech and language (iii) QoL for child and family and (iv) behavioural and emotional measures. Costs will be estimated in a similar way to those in our present studies assessing outcomes in UK children who have had a cochlear implant or a hearing aid.

Key secondary outcome(s)

Not provided at time of registration.

Completion date

31/10/2007

Eligibility

Key inclusion criteria

Children identified with permanent mild or moderate hearing impairment by neonatal screening.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Sex

All

Key exclusion criteria

Not provided at time of registration.

Date of first enrolment

01/04/2001

Date of final enrolment

31/10/2007

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

MRC Institute of Hearing Research

Nottingham

United Kingdom

NG7 2RD

Sponsor information

Organisation

Department of Health (UK)

ROR

<https://ror.org/03sbpja79>

Funder(s)

Funder type

Government

Funder Name

NIHR Health Technology Assessment Programme - HTA (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration